Purchase Order HHSN271201500250P

This is a firm fixed-price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences to A1 Biochem Labs LLC, a small business, for the purchase of 34 intermediate chemical compounds in 5g quantities with purity greater than 95%. The total potential value of the award is $112,350.00. This requirement was set aside for total small business participation and is part of the agency's Coronavirus COVID-19...

This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to AAT Bioquest, Inc., a minority-owned, for-profit, woman-owned small business, and Asian-Pacific American-owned manufacturer of goods. The contract, valued at $161,032.00, is for products or services related to the NIH's mission of accelerating the translation of research to improve human health. The contract does not have a set-aside designation and...

This is a $447,635.80 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. government. The contract is for the "SMALL MOLECULES FOR NCATS PHARMACOLOGICALLY ACTIVE CHEMICAL TOOLBOX (NPACT)" program and was awarded to Analyticon Discovery, LLC, a for-profit foreign-owned organization. The contract does not have a set-aside designation and has an ultimate completion date of January 31, 2016. NCATS is...

<p>This federal contract, awarded by the National Center for Advancing Translational Sciences, a civilian agency, to A1 Biochem Labs LLC, provides for the non-GMP scale up synthesis of a specific chemical compound. The contract is a firm fixed price purchase order with a ceiling value of $24,852.00 and a completion date of October 17, 2024. The contract does not have a set-aside designation. No information is provided about any subcontractors involved in this effort.</p>

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $29,820 firm fixed price purchase order to Medchemexpress LLC to deliver forty-four bioactive compounds for replenishment and expansion of the Mechanism Interrogation PlatE 6.0 screening library. The compounds will support the Center's high-capacity robotic platform used to screen drug combinations and further its chemogenomic screening capabilities. Delivery...

<p>This federal contract award was issued by the National Center for Advancing Translational Sciences, a civilian agency, to AAT Bioquest, Inc. The contract has a ceiling value of $12,570.00 and is a Firm Fixed Price Purchase Order with an ultimate completion date of August 31, 2018. The contract does not have a set-aside designation. Based on the agency and description, this contract is likely related to the agency's research and development efforts in the field of translational sciences.</p>

This is a $90,075 firm fixed price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the U.S. Department of Health and Human Services, to American Biochemicals Inc. The contract is for the synthesis of approximately 50 analogs of the small molecule compound metarrestin, which is being developed as an anti-metastasis agent for pancreatic cancer. The goal is to reduce the brain exposure of the compounds while maintaining their...

This is a federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Compound Focus Inc. for the operation and maintenance of the NCATS Small Molecule Repository. The contract has a ceiling value of $2,093,753.88 and was awarded on June 14, 2016, with a period of performance through June 13, 2017. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, and there is no set-aside designation. The contract is not...

This is a firm-fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), Early Translation Branch (ETB), to Cellmosaic, Inc., a small disadvantaged, woman-owned business, for the synthesis of compound '961. The contract has a ceiling value of $24,738.00 and a period of performance ending on September 8, 2025. The contract was awarded on September 9, 2024 and does not have a set-aside designation. The purpose of the contract is to support the...

<p>The U.S. Federal Agency, Office of Logistics and Acquisition Operations, awarded a Firm Fixed Price Purchase Order contract to 3Xper Innoventure LTD, a foreign-owned for-profit manufacturing organization, to MANUFACTURE THE SMALL MOLECULES TO INCREASE THE TRANSLATIONAL POTENTIAL. The contract has a ceiling value of $24,200.00 and a performance period ending on December 8, 2025. The contract was awarded on December 9, 2024 and does not have a set-aside designation.</p>